NGF analog fusion proteins for antigen specific immunotherapy and methods of use

WO2026085185A3PCT designated stage Publication Date: 2026-05-28AKSTON BIOSCIENCES CORP
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/US2025/051029
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-10-16
Filing Date
2025-10-15
Publication Date
2026-05-28

AI Technical Summary

Technical Problem

Current treatments for chronic pain associated with osteoarthritis in dogs, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and monoclonal antibody therapies, are only partially effective and have adverse side effects, leading to increased suffering and euthanasia due to the complexity and cost of frequent administrations.

Method used

Development of NGF analog-Fc fusion proteins that stimulate the body to produce endogenous antibodies against nerve growth factor (NGF), reducing pain by neutralizing excess NGF and alleviating inflammation through a therapeutic vaccine approach.

Benefits of technology

The NGF analog-Fc fusion proteins provide long-acting, cost-effective pain relief by inducing polyclonal antibodies to neutralize NGF, reducing the need for frequent injections and minimizing side effects, thereby improving the quality of life for dogs with osteoarthritis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2025051029_28052026_PF_FP_ABST
    Figure US2025051029_28052026_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure provides recombinantly manufactured fusion proteins comprising a nerve growth factor (NGF) protein fragment or an analog thereof linked to a canine Fc fragment. Embodiments include the administration of the fusion proteins to patients to reduce pain symptoms in dogs suffering from a pain-associated ailment such as osteoarthritis. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Nerve growth factor mutant

    US20220088139A1

  • Antigen specific immunotherapy for covid-19 fusion proteins and methods of use

    WO2021207599A1

  • Method for screening and / or identifying mutable site in NGF, and method for screening and / or identifying NGF mutant

    WO2024140625A1